Precision BioSciences Inc (NASDAQ:DTIL)

1.54
Delayed Data
As of Jul 01
 -0.06 / -3.75%
Today’s Change
1.11
Today|||52-Week Range
14.38
-79.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$151.0M

Company Description

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Contact Information

Precision BioSciences, Inc.
Dibrell Building
Durham North Carolina 27701
P:(919) 314-5512
Investor Relations:

Employees

Shareholders

Mutual fund holders27.11%
Other institutional21.45%
Individual stakeholders11.21%

Top Executives

Michael AmorosoPresident, Chief Executive Officer & Director
Sinu BhandaruVice President-Operations & Information Technology
John Alexander KellyChief Financial Officer
Jeff SmithChief Technology Officer
Derek N. JantzDirector & Chief Scientific Officer